Electronic specific heat and low energy quasiparticle excitations in superconducting state of La2−xSrxCuO4La_{2-x}Sr_xCuO_4 single crystals

Low temperature specific heat has been measured and extensively analyzed on a series of $La_{2-x}Sr_xCuO_4$ single crystals from underdoped to overdoped regime. From these data the quasiparticle density of states (DOS) in the mixed state is derived and compared to the predicted scaling law $C_{vol}/T\sqrt{H}=f(T/\sqrt{H})$ of d-wave superconductivity. It is found that the scaling law can be nicely followed by the optimally doped sample (x=0.15) in quite wide region of ($T/\sqrt{H} \leq 8 K /\sqrt{T}$). However, the region for this scaling becomes smaller and smaller towards more underdoped region: a clear trend can be seen for samples from x=0.15 to 0.069. Therefore, generally speaking, the scaling quality becomes worse on the underdoped samples in terms of scalable region of $T/\sqrt{H}$. This feature in the underdoped region is explained as due to the low energy excitations from a second order (for example, anti-ferromagnetic correlation, d-density wave, spin density wave or charge density wave order) that may co-exist or compete with superconductivity. Surprisingly, deviations from the d-wave scaling law have also been found for the overdoped sample (x=0.22). While the scaling law is reconciled for the overdoped sample when the core size effect is taken into account. An important discovery of present work is that the zero-temperature data follow the Volovik's relation $\Delta \gamma(T=0)=A\sqrt{H}$ quite well for all samples investigated here although the applicability of the d-wave scaling law to the data at finite temperatures varies with doped hole concentration. Finally we present the doping dependence of some parameters, such as, the residual linear term $\gamma_0$, the $\alpha$ value, etc. ...Comment: 15 pages, 24 figure

ALMA twenty-six arcmin2^2 survey of GOODS-S at one-millimeter (ASAGAO): Near-infrared-dark faint ALMA sources

We report detections of two 1.2 mm continuum sources ($S_\mathrm{1.2mm}$ ~ 0.6 mJy) without any counterparts in the deep $H$- and/or $K$-band image (i.e., $K$-band magnitude $\gtrsim$ 26 mag). These near-infrared-dark faint millimeter sources are uncovered by ASAGAO, a deep and wide-field ($\simeq$ 26 arcmin$^2$) Atacama Large Millimeter/submillimeter Array (ALMA) 1.2 mm survey. One has a red IRAC (3.6 and 4.5 $\mu$m) counterpart, and the other has been independently detected at 850 and 870 $\mu$m using SCUBA2 and ALMA Band 7, respectively. Their optical to radio spectral energy distributions indicate that they can lie at $z \gtrsim$ 3-5 and can be in the early phase of massive galaxy formation. Their contribution to the cosmic star formation rate density is estimated to be ~ 1 $\times$ 10$^{-3}$ $M_\odot$ yr$^{-1}$ Mpc$^{-3}$ if they lie somewhere in the redshift range of $z$ ~ 3-5. This value can be consistent with, or greater than that of bright submillimeter galaxies ($S_\mathrm{870\mu m}>$ 4.2 mJy) at $z$ ~ 3-5. We also uncover 3 more candidates near-infrared-dark faint ALMA sources without any counterparts ($S_\mathrm{1.2mm}$ ~ 0.45-0.86 mJy). These results show that an unbiased ALMA survey can reveal the dust-obscured star formation activities, which were missed in previous deep optical/near-infrared surveys.Comment: 10 pages, 6 figures, accepted for publication in Ap

ALMA 26 Arcmin2^{2} Survey of GOODS-S at One-millimeter (ASAGAO): Average Morphology of High-zz Dusty Star-Forming Galaxies is an Exponential-Disk (n≃1n \simeq 1)

We present morphological properties of dusty star-forming galaxies at z=1-3 determined with high-resolution (FWHM~0"19) Atacama Large Milllimeter/submilimeter Array (ALMA) 1-mm band maps of our ASAGAO survey covering a 26-arcmin^2 area in GOODS-S. In conjunction with the ALMA archival data, the present sample consists of 42 ALMA sources with a wide rest-frame far-infrared (FIR) luminosity L_FIR range of ~10^11-10^13 Lo. To obtain an average rest-frame FIR profile, we perform individual measurements and careful stacking of the ALMA sources using the uv-visibility method that includes positional-uncertainty and smoothing-effect evaluations through Monte-Carlo simulations. We find that the dusty star-forming galaxies have the average FIR-wavelength Sersic index and effective radius of n_FIR=1.2+/-0.2 and R_e,FIR=1.0-1.3 kpc, respectively, additionally with a point source at the center, indicative of the existence of AGN. The average FIR profile agrees with a morphology of an exponential-disk clearly distinguished from a spheroidal profile (Sersic index of 4). We also examine the rest-frame optical Sersic index n_opt and effective radius R_e,opt with the deep Hubble Space Telescope (HST) images. Interestingly, we obtain n_opt=0.9+/-0.3 (~n_FIR) and R_e,opt=3.2+/-0.6 kpc (>R_e,FIR), suggesting that the FIR-emitting disk is embedded within a larger stellar disk. The rest-frame UV and FIR data of HST and ALMA provide us a radial surface density profile of the total star-formation rate (SFR), where the FIR SFR dominates over the UV SFR at the center. Under the simple assumption of a constant SFR, a compact stellar distribution found in z~1-2 compact quiescent galaxies (cQGs) is well reproduced, while a spheroidal stellar morphology of cQGs (n_opt=4) cannot, suggestive of other important mechanisms such as dynamical dissipation.Comment: 13 pages, 6 figures, ApJ in pres

Assessing reproducibility of inherited variants detected with short-read whole genome sequencing

Background: Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant call quality. Systematically assessing reproducibility of inherited variants with WGS and impact of each step in the process is needed for understanding and improving quality of inherited variants from WGS. Results: To dissect the impact of factors involved in detection of inherited variants with WGS, we sequence triplicates of eight DNA samples representing two populations on three short-read sequencing platforms using three library kits in six labs and call variants with 56 combinations of aligners and callers. We find that bioinformatics pipelines (callers and aligners) have a larger impact on variant reproducibility than WGS platform or library preparation. Single-nucleotide variants (SNVs), particularly outside difficult-to-map regions, are more reproducible than small insertions and deletions (indels), which are least reproducible when > 5 bp. Increasing sequencing coverage improves indel reproducibility but has limited impact on SNVs above 30x. Conclusions: Our findings highlight sources of variability in variant detection and the need for improvement of bioinformatics pipelines in the era of precision medicine with WGS.Peer reviewe

Assessing Reproducibility of Inherited Variants Detected With Short-Read Whole Genome Sequencing

Background: Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant call quality. Systematically assessing reproducibility of inherited variants with WGS and impact of each step in the process is needed for understanding and improving quality of inherited variants from WGS. Results: To dissect the impact of factors involved in detection of inherited variants with WGS, we sequence triplicates of eight DNA samples representing two populations on three short-read sequencing platforms using three library kits in six labs and call variants with 56 combinations of aligners and callers. We find that bioinformatics pipelines (callers and aligners) have a larger impact on variant reproducibility than WGS platform or library preparation. Single-nucleotide variants (SNVs), particularly outside difficult-to-map regions, are more reproducible than small insertions and deletions (indels), which are least reproducible when \u3e 5 bp. Increasing sequencing coverage improves indel reproducibility but has limited impact on SNVs above 30×. Conclusions: Our findings highlight sources of variability in variant detection and the need for improvement of bioinformatics pipelines in the era of precision medicine with WGS

The 2020 UV emitter roadmap

Solid state UV emitters have many advantages over conventional UV sources. The (Al,In,Ga)N material system is best suited to produce LEDs and laser diodes from 400 nm down to 210 nm—due to its large and tuneable direct band gap, n- and p-doping capability up to the largest bandgap material AlN and a growth and fabrication technology compatible with the current visible InGaN-based LED production. However AlGaN based UV-emitters still suffer from numerous challenges compared to their visible counterparts that become most obvious by consideration of their light output power, operation voltage and long term stability. Most of these challenges are related to the large bandgap of the materials. However, the development since the first realization of UV electroluminescence in the 1970s shows that an improvement in understanding and technology allows the performance of UV emitters to be pushed far beyond the current state. One example is the very recent realization of edge emitting laser diodes emitting in the UVC at 271.8 nm and in the UVB spectral range at 298 nm. This roadmap summarizes the current state of the art for the most important aspects of UV emitters, their challenges and provides an outlook for future developments

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Large expert-curated database for benchmarking document similarity detection in biomedical literature search

Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362